‘Alexa, do I have Parkinson’s?’; aim for 7,000 steps a day; FDA failing to curb illegal GLP-1 compounding, says CMPI – Morning Medical Update

Morning Medical Update © Diego - stock.adobe.com

Alexa, do I have Parkinson’s?

University of Rochester researchers have developed a web-based artificial intelligence (AI) tool that analyzes speech to detect signs of Parkinson’s disease. Users recite two short sentences, and the system — trained on over 1,300 participants — can flag vocal patterns associated with Parkinson’s with 86% accuracy. Though not a diagnostic device, the tool could be integrated into voice assistants like Amazon Alexa or Google Home to help identify early symptoms in underserved areas.

7,000 steps a day tied to major health benefits

A new analysis in The Lancet Public Health finds that walking around 7,000 steps daily can slash the risk of chronic diseases, cognitive decline and premature death. Based on data from over 160,000 adults, the study links this modest step count to lower risks of heart disease, diabetes, dementia, depression and more — and it's more achievable the commonly cited 10,000 steps.

FDA failing to curb illegal GLP-1 compounding

A report from the Center for Medicine in the Public Interest (CMPI) accuses the Food and Drug Administration (FDA) of allowing dangerous, unregulated GLP-1 drugs to flood the U.S. market. Authored by Peter J. Pitts, president of CMPI and former associate commissioner of the FDA, the report highlights patient harms tied to mass-compounded semaglutide and tirzepatide made with foreign ingredients and marketed deceptively as safe alternatives. Despite the end of drug shortages, compounders continue selling unapproved versions under false pretenses. Pitts calls the agency’s inaction “a public health crisis in the making” and urges swift enforcement to halt black market production and protect patients. Read more from Pharmaceutical Executive.